MAGED2

Across TCGA pan-cancer cohorts, MAGED2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAGED2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MAGED2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAGED2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, UCEC, and THCA are the cancer types where MAGED2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.131	0.800	<.001	21	view →
UCEC	DFS	Median	All	0.946	0.613	.005	20	view →
THCA	DFS	Median	All	0.100	0.841	<.001	18	view →
LUAD	OS	Median	All	0.398	0.703	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAGED2–COAD (OS)

Open the COAD breakdown →